{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-031964","form_type":"8-K","ticker":"ABVC","cik":"0001173313","company_name":"ABVC BIOPHARMA, INC.","filed_at":"2023-04-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.143195+00:00","generated_at":"2026-06-16T18:28:29.498948+00:00","sec_items":["5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"confidence":"high","headline":"ABVC BioPharma shareholders re-elect 11 directors, ratify auditor, approve share issuance for Lind note conversion","bullets":["All 11 director nominees re-elected; votes ranged from 18.79M to 18.86M for, with 0 against.","Ratification of WWC P.C. as auditor for FY 2023: 19,388,899 for, 86,207 against, 5,010 abstain.","Authorization to issue shares underlying convertible notes and warrants to Lind Global Fund II LP passed: 18,835,192 for, 115,688 against.","Quorum of 19,480,116 shares (58.88% voting power) represented at meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-031964","json":"https://secwatch.observer/filing/0001213900-23-031964.json","markdown":"https://secwatch.observer/filing/0001213900-23-031964.md","text":"https://secwatch.observer/filing/0001213900-23-031964.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1173313/000121390023031964/0001213900-23-031964-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1173313/000121390023031964/ea177375-8k_abvcbio.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T18:28:29.498948+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1980c7490be17d3fe01c163326c247a47a15d3c6","claim":"ABVC BIOPHARMA, INC. shareholders approved Authorization of issuance of shares of common stock underlying convertible notes and warrants to Lind Global Fund II, LP in compliance with Nasdaq Listing Rule 5635(d) at the 2023-04-24 meeting.","evidence_excerpt":"3. To authorize, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of shares of our common stock underlying convertible notes and warrants issued by us pursuant to the terms of that certain Securities Purchase Agreement, dated February 23, 2023, by and among the Company and Lind Global Fund II, LP (“Lind”) , in an amount equal to or in excess of 20% of our common stock outstanding immediately prior to the issuance of such convertible note and warrants (including upon the operation of anti-dilution provisions contained in such convertible preferred stock and warrants. For Against Abstain 18,835,192 115,688 529,236","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1173313/000121390023031964/0001213900-23-031964-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-04-24"}],"fact_type":"shareholder_vote"},{"claim_id":"891c68a67bdf1c528d357c17a8860bd49c075916","claim":"ABVC BIOPHARMA, INC. shareholders approved Ratification of the appointment of WWC P.C. CPA as the independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-04-24 meeting.","evidence_excerpt":"2. To ratify the appointment of WWC P.C. CPA as the Company’s independent registered public accounting firm for fiscal year ending December 31, 2023. For Against Abstain 19,388,899 86,207 5,010","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1173313/000121390023031964/0001213900-23-031964-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-04-24"}],"fact_type":"shareholder_vote"},{"claim_id":"e477ec122a6b1505e91753f254cf994f3c76ee3e","claim":"ABVC BIOPHARMA, INC. shareholders approved Re-election of 11 directors to the Company's board of directors, to serve until the 2024 annual meeting of shareholders at the 2023-04-24 meeting.","evidence_excerpt":"1. To re-elect 11 directors to the Company’s board of directors (the “ Board ”), with such directors to serve until the 2024 annual meeting of shareholders. Name For Against Withheld Eugene Jiang 18,840,814 0 639,302 Norimi Sakamoto 18,796,356 0 683,760 Yen-Hsin Chou 18,833,715 0 646,401 Dr. Tsung-Shann (T.S.) Jiang 18,831,765 0 648,351 Hsin-Hui Miao 18,831,735 0 648,381 Yoshinobu Odaira 18,798,388 0 681,728 Dr. Tsang Ming Jiang 18,831,785 0 648,331 Dr. Chang-Jen Jiang 18,833,765 0 646,351 Che Wei Hsu 18,789,099 0 691,017 Shuling Jiang 18,855,080 0 625,036 Yu-Min (Francis) Chung 18,840,845 0 639,271","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1173313/000121390023031964/0001213900-23-031964-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-04-24"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}